Amendments to the Claims:

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.-104. (Canceled)

105. (New) A compound of formula



I

wherein

R^1 is methyl,

R^2 is hydrogen,

n is 0, 1 or 2,

R^3 is cyclopropyl,

Y is -C(=O)NH-,

X^1 is a single bond or alkylene,

A, X^2 and D are a pyrazolopyrimidine group of formula III



k is an integer from 0 to 4,

w is an integer from 0 to 4,

R^{13} is hydrogen, alkyl, OH or NH_2, and

$(CR^9R^{10})_wE$ is alkyl, alkoxy, halo, $-CH_2$-heterocyclyl, -CONH-cycloalkyl, alkylsulfonyl, alkylthio, alkylsulfonylamino, haloalkyl, aminocarbonyl, pseudohalo or heterocyclyl, or two $(CR^9R^{10})_wE$ groups, which substitute adjacent atoms on D, together form alkylenedioxy,

wherein

alkyl is lower alkyl having 1 to 6 carbon atoms,

alkylene is lower alkylene having 1 to 6 carbons,

haloalkyl is an alkyl group in which one or more of the hydrogen atoms are replaced by halogen
cycloalkyl is to a saturated mono- or multicyclic ring system of 3 to 10 carbon atoms,
alkoxy is RO-,
alkylthio is RS-,
R is lower alkyl having 1 to 6 carbon atoms
pseudohalo is cyanide, cyanate, thiocyanate, selenocyanate, trifluoromethoxy, or azido and
heterocyclyl is a monocyclic or multicyclic non-aromatic ring system of 3 to 10 members where 1 to 3, of the atoms in the ring system is a heteroatom selected from nitrogen, oxygen or sulfur.

106. (New) A compound according to claim 105, wherein X^1 is a single bond.

107. (New) A compound according to claim 105, which is selected from the group consisting of:
N-Cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide,
N-Cyclopropyl-3-[4-(2-methoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide,
N-Cyclopropyl-3-[4-(4-methanesulfonyl-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide, N-Cyclopropyl-3-[4-(3,4-dimethoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide, N-Cyclopropyl-3-[4-(4-methoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide, N-Cyclopropyl-4-methyl-3-{4-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-pyrazolo[3,4-d]pyrimidin-1-yl}-benzamide,
N-Cyclopropyl-3-[4-(3-ethoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide,
N-Cyclopropyl-3-[4-(3-iodo-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide,
N-Cyclopropyl-3-[4-(3-methoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide,
N-Cyclopropyl-3-(6-hydroxy-4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-4-methyl-benzamide, and
N-Cyclopropyl-4-methyl-3-{4-[3-(4H-[1,2,4]triazol-3-yl)-phenyl]-pyrazolo[3,4-d]pyrimidin-1-yl}-benzamide.

108. (New) A compound according to claim 105 in the form of a pharmaceutically acceptable salt.

109. (New) A pharmaceutical composition comprising a compound of claim 105 and a pharmaceutically acceptable carrier.

110. (New) A method of treating a disease that is modulated or otherwise affected by cytokine activity or in which cytokine activity is implicated, wherein the cytokine activity is modulated by p38 kinase, comprising administering to a patient in need thereof an effective amount of a compound of claim 105.

111. (New) A method of reducing the expression of inducible pro-inflammatory proteins, wherein the pro-inflammatory protein is prostaglandin endoperoxide synthase-2 (PGHS-2), comprising administering to a patient in need thereof an effective amount of a compound of claim 105.

112. (New) A method of treating a disease associated with inducible pro-inflammatory proteins, wherein the disease is selected from edema, analgesia, fever, pain, neuromuscular pain, headache, pain caused by cancer, dental pain and arthritis pain, comprising administering to a subject in need thereof a compound of claim 105.

113. (New) A method of inhibiting p38 kinase activity, comprising administering to a patient in need thereof an effective amount of a compound of claim 105.

114. (New) A method of inhibiting the activity of a kinase protein, wherein the kinase protein is a tyrosine kinase protein, comprising contacting the protein with a compound of claim 105.

115. (New) A method of inhibiting the activity of a kinase protein, wherein the kinase protein is FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2 or VEGFR, comprising contacting the protein with a compound of claim 105.

116. (New) A method of treating a disease characterized by deregulation of the activity of a kinase protein, comprising administering a compound of claim 105.

117. (New) A method of treating a disorder of the proliferation of blood vessels, a fibrotic disorder, a disorder of the proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration or cancer, comprising administering a compound of claim 105.

118. (New) A method of treating a disease associated with uncontrolled angiogenesis, comprising administering a compound of claim 105.

119. (New) A method of treating an oncologic disease, comprising administering a compound of claim 105.

120. (New) A method of treating cancer comprising administering a compound of claim 105.

121. (New) The method of claim 120, wherein the disease is a solid tumor.

122. (New) The method of claim 120, wherein the cancer is resistant to cytotoxic agents.

123. (New) The method of claim 120, wherein the cancer is breast cancer, stomach cancer, cancer of the ovaries, cancer of the colon, lung cancer, brain cancer, cancer of the larynx, cancer of the lymphatic system, cancer of the genito-urinary tract including the bladder and the prostate, bone cancer, and cancer of the pancreas.